Pharmaceutical Stocks

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?

Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'

Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?

Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'

This $5B Pharmaceutical Could Benefit From Over-The-Counter Contraceptives And Plan B Alternatives

36 Stocks To Watch After Biden's First State of The Union Address

This $5B Pharmaceutical Could Benefit From Over-The-Counter Contraceptives And Plan B Alternatives

36 Stocks To Watch After Biden's First State of The Union Address

Jim Lebenthal Likes AbbVie Stock At Its Current Price

Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers

Pharmaceutical Stocks Recent News

Valeant Investors: Cantor Says It's Time To Stop Waiting For The Other Shoe To Drop

Johnson & Johnson's Sales Slump Has Played Itself Out, Could Reaccelerate This Year

The Street Is Misreading Sarepta's Guidance

Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive

Analysts Having Difficulty Getting Comfortable With Valeant's Fundamentals

Last Night's Election - A Series Of Fortunate Events For Big Pharma

Valeant's Salix Story: To Sell Or Not To Sell?

Benzinga Talks With Imprimis Pharmaceuticals' CEO About Earnings, MKO Melt, Drug Pricing And More

AbbVie Shares Trading At A Discount To Other Pharmaceuticals; Argus Reaffirms With A Buy Rating

Importance Of Phase 1 Trials

Acorda Dips 2%, Company Says It Will Discontinue Development Of Nasal Spray

Regeneron Gains 4% Following Q1 Earnings Release

B. Riley Cuts Perrigo's Price Target From $146 To $113 On Papa's Exit, FY16 Guidance

Pharma Names Under Pressure Amid Perrigo Warning

Allergan Announces Acquisition Of Topokine Therapeutics, Highlights Fat Reduction Development Program

Kite Pharma Gains 2% After Management Provides Update To A Phase 1 Study

This Explains Horizon Pharma's 25% Plunge

Biogen's Stock Pops Following Better-Than-Expected Q4 Results

Relypsa Up 10% Following Encouraging Phase 1 Study Results

Shares Of Catabasis Pharmaceuticals See-Saw Following Results Of Duchenne Muscular Dystrophy Study

Agile Therapeutics Plunges After Company Prices A Stock Offering At $6.35 Per Share

Vetr Top Raters Upgrade Mannkind To 4.5-Star Stock

These Three Pharma Giants Just Crushed Earnings